Placebo-controlled trial of terlipressin (glypressin) in the management of acute variceal bleeding.
In a double-blind trial 60% of acute variceal bleeding episodes were controlled with terlipressin (glypressin) compared with 37% in patients given placebo (NS). Rebleeding was more common in the placebo group so that at 5 days bleeding remained under control in 54% of patients treated with terlipressin compared with only 19% after placebo therapy (p less than 0.025). Blood transfusion requirements were similar in the two groups. Terlipressin appeared to be the most effective in those patients with severe hepatic dysfunction.
Freeman
J G
JG
Gastroenterology Unit, Royal Victoria Infirmary, Newcastle Upon Tyne, England.
Cobden
I
I
Record
C O
CO
D000208:Acute Disease; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004932:Esophageal and Gastric Varices / Q000209:etiology / Q000628:therapy*; D006471:Gastrointestinal Hemorrhage / Q000209:etiology / Q000628:therapy*; D006801:Humans; D008108:Liver Diseases, Alcoholic / Q000150:complications; D008236:Lypressin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008875:Middle Aged; D011897:Random Allocation; D012008:Recurrence; D000077585:Terlipressin
D008236:Lypressin; D000077585:Terlipressin